Piper Sandler Raises Bristol Myers (BMY) PT to $66 Citing Pipeline Visibility

Core Insights - Bristol Myers Squibb Company (NYSE:BMY) is identified as one of the most undervalued large-cap stocks currently available for investment [1] - Analysts have raised price targets for Bristol Myers, indicating a positive outlook for the stock driven by pipeline progress and growth potential [2][3] Analyst Ratings and Price Targets - Piper Sandler increased its price target for Bristol Myers to $66 from $62, maintaining an Overweight rating, citing undervaluation due to the upcoming loss of exclusivity for Eliquis in the US [1] - Citi analyst Geoff Meacham raised the price target to $60 from $53 with a Neutral rating, highlighting favorable conditions for the biopharma sector heading into 2026 [2] - Leerink analyst David Risinger raised the price target to $60 from $54 with an Outperform rating, anticipating significant upside potential in 2026 due to a robust pipeline [3] Company Overview - Bristol Myers Squibb is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products globally, focusing on areas such as oncology, hematology, immunology, cardiovascular, and neuroscience [4]